Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Accumulated Expenses data on file, last reported at $19.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 31.6% year-over-year to $19.2 million; the trailing twelve-month figure through Mar 2026 stood at $19.2 million (up 31.6% YoY), and the FY2025 full-year result was $18.9 million, down 4.57% from the prior year.
• Accumulated Expenses improved to $19.2 million in Q1 2026, from $18.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.9 million in Q4 2024 to a low of $9.4 million in Q1 2022.
• A 5-year average of $14.0 million and a median of $13.2 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 109.24% in 2022 and tumbled 39.12% in 2023, its largest moves.
• Tracing SLDB's Accumulated Expenses over 5 years: stood at $16.7 million in 2022, then plunged by 39.12% to $10.2 million in 2023, then soared by 95.37% to $19.9 million in 2024, then decreased by 4.57% to $18.9 million in 2025, then rose by 1.25% to $19.2 million in 2026.
• Business Quant data shows SLDB's Accumulated Expenses at $19.2 million in Q1 2026, $18.9 million in Q4 2025, and $19.0 million in Q3 2025.